A CAF subpopulation promotes LVI in early-stage bladder cancer

IF 12.1 1区 医学 Q1 UROLOGY & NEPHROLOGY Nature Reviews Urology Pub Date : 2024-04-15 DOI:10.1038/s41585-024-00881-z
Maria Chiara Masone
{"title":"A CAF subpopulation promotes LVI in early-stage bladder cancer","authors":"Maria Chiara Masone","doi":"10.1038/s41585-024-00881-z","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":null,"pages":null},"PeriodicalIF":12.1000,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Urology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41585-024-00881-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CAF 亚群可促进早期膀胱癌的 LVI
发表在《癌细胞》(Cancer Cell)上的一篇新文章显示,癌症相关成纤维细胞(CAFs)亚群在促进早期膀胱癌淋巴管侵袭(LVI)方面发挥着关键作用。在这项研究中,对膀胱癌患者组织样本的LVI分析表明,早期患者的LVI与淋巴结(LN)转移率增加和预后不良有关。单细胞 RNA 测序分析表明,PDGFRα+ITGA11+ CAFs 在 LVI 阳性的早期膀胱癌患者中特别富集。这种 CAF 亚群的存在与预后不良和 LVI 相关。在膀胱癌小鼠模型中条件性敲除 PDGFRα+ITGA11+ CAFs 可大大减少 LVI 和 LN 转移,这表明这一 CAF 群体在 LVI 中起着至关重要的作用。从机理上讲,PDGFRα+ITGA11+ CAFs在体外以依赖ITGA11的方式附着在人淋巴内皮细胞(HLECs)上,因为在缺乏ITGA11的情况下这种附着会受损。表面受体 SELE 被鉴定为 HLECs 上最强的 ITGA11 结合伙伴,在 LVI 阳性与 LVI 阴性早期膀胱癌患者的组织样本中观察到 ITGA11 与 SELE 的相互作用增强。PDGFRα+ITGA11+CAF迁移和附着到HLECs需要SELE。此外,基因敲除 SELE 或 ITGA11 后,膀胱癌细胞在体外的跨内皮迁移减少。从机理上讲,ITGA11-SELE 的相互作用被证明能促进 HLECs 中的 VEGFR3 磷酸化和随后的 MAPK 通路激活,进而促进膀胱癌细胞的跨内皮迁移。有证据表明,VEGFR-MAPK 的激活本身不足以促进膀胱癌 LVI 和 LN 转移,这促使作者研究 PDGFRα+ITGA11+ CAFs 是否存在由其他因素介导的其他机制。在 PDGFRα+ITGA11+ CAFs 中观察到了细胞外基质(ECM)重塑基因的上调,并证明这种 ECM 重塑可通过 ECM 重塑细胞因子 CHI3L1 的过表达增加膀胱癌细胞球体的迁移。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Nature Reviews Urology
Nature Reviews Urology 医学-泌尿学与肾脏学
CiteScore
12.50
自引率
2.60%
发文量
123
审稿时长
6-12 weeks
期刊介绍: Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.
期刊最新文献
Prostate cancer in transgender women — challenges in research and clinical care Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer 20 years of ‘spilling the tea’ in urology Author Correction: Metaverse in surgery - origins and future potential. Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwards
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1